Please upgrade your browser

We built this website using the latest browser technologies to deliver the very best experience.

This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.

We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.

Download ChromeDownload Microsoft Edge
Press release

Sensyne Health announces one year agreement with Exscientia to utilise real-world data platform

Agreement includes an upfront payment for four SENSIGHT subscriptions and associated professional services.

December 24, 2021

Oxford, U.K. – 24th December 2021 Sensyne Health plc (LSE:SENS or “the Company”) today announced a one-year agreement with Exscientia to leverage the deep learning AI capabilities of the Sensyne platform to study real-world health data.  

Under the terms of the agreement, Exscientia will make an upfront payment for four SENSIGHT subscriptions and a project-based fee, with a 40/60 split between the two. Sensyne will apply its data science expertise to create bespoke data sets from its database of patient records to answer project-specific questions regarding biomarker discovery and targets for new medicines. Sensyne’s collaborative relationship with the United Kingdom’s National Health Service (NHS) means the Company is able to capture a more complete record of a patient’s treatment over a longer period of time than is typically possible. 

“We look forward to having the opportunity to leverage insights from Sensyne’s platform. We believe having access to this real-world health data will not only potentially enhance our discovery of biomarkers, but also aid in patient selection for clinical trials.” 

said Dr. Dan Crowther, VP of Bioinformatics at Exscientia.  

The collaboration will use the SENSIGHT platform to enable the ethical analysis of anonymised patient data from Sensyne’s growing network of strategic research partnerships with NHS Trusts in the UK and health systems in the United States, currently totalling 48.3 million patients [1]. 

Lord (Paul) Drayson PhD FREng, Founder and Chief Executive Officer of Sensyne, commented: 

“Exscientia is a leader in AI-driven drug discovery and has already brought several AI-designed drug candidates to the clinical trial stage.  We are excited about the opportunity to explore how we can work together to apply AI throughout the drug development process to bring new medicines to patients faster and more cost effectively.”

SENSIGHT is a clinical AI platform that provides industrial scale access to insights from anonymised and de-identified RWD, across multiple therapy areas, from Sensyne’s partner healthcare organisations in the UK and US, combined with built-in simple to use research algorithms. The platform provides life science professionals, medical research academics and clinicians with instant access to AI research capability to analyse health insights to inform decision making, generate deeper insights into patient journeys and improve the speed and outcomes of clinical trials. 

[1] Comprising 26.3 million de-identified patient data records (12.9million in UK and 13.4 million patients in the US) together with a further 22.0 million available in the US through a teaming agreement with OMNY Health

Press release

Sensyne Health announces one year agreement with Exscientia to utilise real-world data platform

December 24, 2021
Agreement includes an upfront payment for four SENSIGHT subscriptions and associated professional services.

Oxford, U.K. – 24th December 2021 Sensyne Health plc (LSE:SENS or “the Company”) today announced a one-year agreement with Exscientia to leverage the deep learning AI capabilities of the Sensyne platform to study real-world health data.  

Under the terms of the agreement, Exscientia will make an upfront payment for four SENSIGHT subscriptions and a project-based fee, with a 40/60 split between the two. Sensyne will apply its data science expertise to create bespoke data sets from its database of patient records to answer project-specific questions regarding biomarker discovery and targets for new medicines. Sensyne’s collaborative relationship with the United Kingdom’s National Health Service (NHS) means the Company is able to capture a more complete record of a patient’s treatment over a longer period of time than is typically possible. 

“We look forward to having the opportunity to leverage insights from Sensyne’s platform. We believe having access to this real-world health data will not only potentially enhance our discovery of biomarkers, but also aid in patient selection for clinical trials.” 

said Dr. Dan Crowther, VP of Bioinformatics at Exscientia.  

The collaboration will use the SENSIGHT platform to enable the ethical analysis of anonymised patient data from Sensyne’s growing network of strategic research partnerships with NHS Trusts in the UK and health systems in the United States, currently totalling 48.3 million patients [1]. 

Lord (Paul) Drayson PhD FREng, Founder and Chief Executive Officer of Sensyne, commented: 

“Exscientia is a leader in AI-driven drug discovery and has already brought several AI-designed drug candidates to the clinical trial stage.  We are excited about the opportunity to explore how we can work together to apply AI throughout the drug development process to bring new medicines to patients faster and more cost effectively.”

SENSIGHT is a clinical AI platform that provides industrial scale access to insights from anonymised and de-identified RWD, across multiple therapy areas, from Sensyne’s partner healthcare organisations in the UK and US, combined with built-in simple to use research algorithms. The platform provides life science professionals, medical research academics and clinicians with instant access to AI research capability to analyse health insights to inform decision making, generate deeper insights into patient journeys and improve the speed and outcomes of clinical trials. 

[1] Comprising 26.3 million de-identified patient data records (12.9million in UK and 13.4 million patients in the US) together with a further 22.0 million available in the US through a teaming agreement with OMNY Health

Press release

Sensyne Health announces one year agreement with Exscientia to utilise real-world data platform

Sensyne Health announces one year agreement with Exscientia to utilise real-world data platform

December 24, 2021
Agreement includes an upfront payment for four SENSIGHT subscriptions and associated professional services.

Oxford, U.K. – 24th December 2021 Sensyne Health plc (LSE:SENS or “the Company”) today announced a one-year agreement with Exscientia to leverage the deep learning AI capabilities of the Sensyne platform to study real-world health data.  

Under the terms of the agreement, Exscientia will make an upfront payment for four SENSIGHT subscriptions and a project-based fee, with a 40/60 split between the two. Sensyne will apply its data science expertise to create bespoke data sets from its database of patient records to answer project-specific questions regarding biomarker discovery and targets for new medicines. Sensyne’s collaborative relationship with the United Kingdom’s National Health Service (NHS) means the Company is able to capture a more complete record of a patient’s treatment over a longer period of time than is typically possible. 

“We look forward to having the opportunity to leverage insights from Sensyne’s platform. We believe having access to this real-world health data will not only potentially enhance our discovery of biomarkers, but also aid in patient selection for clinical trials.” 

said Dr. Dan Crowther, VP of Bioinformatics at Exscientia.  

The collaboration will use the SENSIGHT platform to enable the ethical analysis of anonymised patient data from Sensyne’s growing network of strategic research partnerships with NHS Trusts in the UK and health systems in the United States, currently totalling 48.3 million patients [1]. 

Lord (Paul) Drayson PhD FREng, Founder and Chief Executive Officer of Sensyne, commented: 

“Exscientia is a leader in AI-driven drug discovery and has already brought several AI-designed drug candidates to the clinical trial stage.  We are excited about the opportunity to explore how we can work together to apply AI throughout the drug development process to bring new medicines to patients faster and more cost effectively.”

SENSIGHT is a clinical AI platform that provides industrial scale access to insights from anonymised and de-identified RWD, across multiple therapy areas, from Sensyne’s partner healthcare organisations in the UK and US, combined with built-in simple to use research algorithms. The platform provides life science professionals, medical research academics and clinicians with instant access to AI research capability to analyse health insights to inform decision making, generate deeper insights into patient journeys and improve the speed and outcomes of clinical trials. 

[1] Comprising 26.3 million de-identified patient data records (12.9million in UK and 13.4 million patients in the US) together with a further 22.0 million available in the US through a teaming agreement with OMNY Health

Press release

Sensyne Health announces one year agreement with Exscientia to utilise real-world data platform

Agreement includes an upfront payment for four SENSIGHT subscriptions and associated professional services.

Oxford, U.K. – 24th December 2021 Sensyne Health plc (LSE:SENS or “the Company”) today announced a one-year agreement with Exscientia to leverage the deep learning AI capabilities of the Sensyne platform to study real-world health data.  

Under the terms of the agreement, Exscientia will make an upfront payment for four SENSIGHT subscriptions and a project-based fee, with a 40/60 split between the two. Sensyne will apply its data science expertise to create bespoke data sets from its database of patient records to answer project-specific questions regarding biomarker discovery and targets for new medicines. Sensyne’s collaborative relationship with the United Kingdom’s National Health Service (NHS) means the Company is able to capture a more complete record of a patient’s treatment over a longer period of time than is typically possible. 

“We look forward to having the opportunity to leverage insights from Sensyne’s platform. We believe having access to this real-world health data will not only potentially enhance our discovery of biomarkers, but also aid in patient selection for clinical trials.” 

said Dr. Dan Crowther, VP of Bioinformatics at Exscientia.  

The collaboration will use the SENSIGHT platform to enable the ethical analysis of anonymised patient data from Sensyne’s growing network of strategic research partnerships with NHS Trusts in the UK and health systems in the United States, currently totalling 48.3 million patients [1]. 

Lord (Paul) Drayson PhD FREng, Founder and Chief Executive Officer of Sensyne, commented: 

“Exscientia is a leader in AI-driven drug discovery and has already brought several AI-designed drug candidates to the clinical trial stage.  We are excited about the opportunity to explore how we can work together to apply AI throughout the drug development process to bring new medicines to patients faster and more cost effectively.”

SENSIGHT is a clinical AI platform that provides industrial scale access to insights from anonymised and de-identified RWD, across multiple therapy areas, from Sensyne’s partner healthcare organisations in the UK and US, combined with built-in simple to use research algorithms. The platform provides life science professionals, medical research academics and clinicians with instant access to AI research capability to analyse health insights to inform decision making, generate deeper insights into patient journeys and improve the speed and outcomes of clinical trials. 

[1] Comprising 26.3 million de-identified patient data records (12.9million in UK and 13.4 million patients in the US) together with a further 22.0 million available in the US through a teaming agreement with OMNY Health

Arrange to meet us
Press release

Sensyne Health announces one year agreement with Exscientia to utilise real-world data platform

December 24, 2021
Agreement includes an upfront payment for four SENSIGHT subscriptions and associated professional services.

Oxford, U.K. – 24th December 2021 Sensyne Health plc (LSE:SENS or “the Company”) today announced a one-year agreement with Exscientia to leverage the deep learning AI capabilities of the Sensyne platform to study real-world health data.  

Under the terms of the agreement, Exscientia will make an upfront payment for four SENSIGHT subscriptions and a project-based fee, with a 40/60 split between the two. Sensyne will apply its data science expertise to create bespoke data sets from its database of patient records to answer project-specific questions regarding biomarker discovery and targets for new medicines. Sensyne’s collaborative relationship with the United Kingdom’s National Health Service (NHS) means the Company is able to capture a more complete record of a patient’s treatment over a longer period of time than is typically possible. 

“We look forward to having the opportunity to leverage insights from Sensyne’s platform. We believe having access to this real-world health data will not only potentially enhance our discovery of biomarkers, but also aid in patient selection for clinical trials.” 

said Dr. Dan Crowther, VP of Bioinformatics at Exscientia.  

The collaboration will use the SENSIGHT platform to enable the ethical analysis of anonymised patient data from Sensyne’s growing network of strategic research partnerships with NHS Trusts in the UK and health systems in the United States, currently totalling 48.3 million patients [1]. 

Lord (Paul) Drayson PhD FREng, Founder and Chief Executive Officer of Sensyne, commented: 

“Exscientia is a leader in AI-driven drug discovery and has already brought several AI-designed drug candidates to the clinical trial stage.  We are excited about the opportunity to explore how we can work together to apply AI throughout the drug development process to bring new medicines to patients faster and more cost effectively.”

SENSIGHT is a clinical AI platform that provides industrial scale access to insights from anonymised and de-identified RWD, across multiple therapy areas, from Sensyne’s partner healthcare organisations in the UK and US, combined with built-in simple to use research algorithms. The platform provides life science professionals, medical research academics and clinicians with instant access to AI research capability to analyse health insights to inform decision making, generate deeper insights into patient journeys and improve the speed and outcomes of clinical trials. 

[1] Comprising 26.3 million de-identified patient data records (12.9million in UK and 13.4 million patients in the US) together with a further 22.0 million available in the US through a teaming agreement with OMNY Health